Behbahani Ali sold $781K of CRSP

Behbahani Ali sold 13,679 shares of CRISPR Therapeutics AG (CRSP) at $57.09 ($0.78M total) on 2026-09-17.

Original reporting
SEC EDGAR · Behbahani Ali
Published Sep 21, 2026, 10:40 PM UTC
Analysis
AlphAI AI DeskAI-generated
Added to AlphAI Sep 22, 2026, 12:03 AM UTC. Informational, not investment advice.
How this was made
AlphAI summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.
AlphAI market briefInsider activity
Primary signal
$CRSP
Bearish
medium confidence
Mentioned
$CRSP
Relevance
5/10
AlphAI data visualization · based on SEC EDGAR
Decision brief

The 30-second read

$CRSPBearishLow
01

Why it matters

The disclosed sale reduces insider ownership, which may be interpreted as a negative signal by the market.

02

Market read

Insider sales are closely watched; this modest sale may cause slight short-term price movement.

03

What to watch

Potential upcoming corporate actions or financing needs not disclosed in the filing.

Relevance 5/10Novelty 4/10Timing: post-market filing on Sep 21, 2026

Background

SEC Form 4 filings disclose insider transactions. This filing reports a director's sale of CRISPR Therapeutics shares.

Company-level read

Ticker impact

$CRSPBearishMedium confidence
Context

Director Behbahani Ali sold 13,679 shares of CRISPR Therapeutics for $781K, reducing his stake to 16,637 shares.

Expected impact

Modest downward pressure over the next few trading sessions.

Evidence & confidence

A $781K sale by a director is a material insider transaction, but the amount is modest relative to market cap, limiting impact.

Market effects

Minimal; the sale does not affect the broader biotech sector.

None; the transaction is company-specific.

Low; limited to CRISPR Therapeutics investors.

Counterpoint

The sale could be a routine liquidity event unrelated to company fundamentals.

Key entities

  • CRISPR Therapeutics AG

    Biotech firm developing CRISPR gene-editing therapies.

  • Behbahani Ali

    Director of CRISPR Therapeutics.

Full insider trading history

This story covers one filing. See everything behind it: every insider buy and sell on record, 10b5-1 plans, late filings, and which officers and directors are trading.

Related articles

$CRSPMed

Seawolf Therapeutics San Diego $100M Sanofi DNA Deal

Seawolf Therapeutics, a San Diego biotech, raised $100M and partnered with Sanofi for a deal potentially worth $1.2B. The company's TRIDENT platform aims to enable repeat dosing of gene therapies. Seawolf's lead program targets metabolic diseases, with human trials expected by 2028. Investors include Eli Lilly, Novartis Venture Fund, and CRISPR Therapeutics.

$CRSPHighAI 8/10

Piper Sandler reiterates CRISPR Therapeutics stock rating at overweight

Piper Sandler maintained an Overweight rating and $110 price target for CRISPR Therapeutics (CRSP) after positive clinical data presentations. CTX310 showed significant reductions in lipid parameters, while zugo-cel demonstrated high response rates in various diseases. CRSP reported Q3 2026 sales of $99M for CASGEVY and holds $2.36B in cash. Analysts have mixed views on its valuation and price targets.

$CRSPMedAI 8/10

CRISPR Therapeutics reports trial results for gene therapy CTX310

CRISPR Therapeutics (CRSP) reported Phase 1b trial results for CTX310, a gene therapy for severe hypertriglyceridemia. The trial showed significant reductions in triglycerides, ANGPTL3 protein, and other cholesterol markers. No serious adverse events were reported. The FDA has granted RMAT designations to CTX310 for this indication and for elevated LDL cholesterol.